anti-CD3/anti-BCMA bispecific T-cell engager (Promab Biotechnologies/Forevertek Biotechnology)

N/A

Report date: 2026/03/24 20:00:35

Base Information

Drug Nameanti-CD3/anti-BCMA bispecific T-cell engager (Promab Biotechnologies/Forevertek Biotechnology)
Drug Alias NameBCMA-CD3scFv CrossMab KIH (Promab Biotechnologies/Forevertek Biotechnology)
ClassificationBiologics > T cell engagersBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibody
Mechanisms of ActionAnti-BCMACD3 T-cell engagers
TargetsB-cell maturation proteinT cell surface glycoprotein CD3
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesForevertek Biotechnology Co LtdProMab Biotechnologies Inc
China Registration ClassN/A

Develop Information

Active CompaniesProMab Biotechnologies IncForevertek Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A